Synapse

← Meletios Α. Dimopoulos

Papers by Meletios Α. Dimopoulos

Page 6 · newest first

  1. Immune response and adverse events after vaccination against SARS‐CoV ‐2 in adult patients with transfusion‐dependent thalassaemiaBritish Journal of Haematology · 2022
  2. The COMPASS-COVID-19-ICU Study: Identification of Factors to Predict the Risk of Intubation and Mortality in Patients with Severe COVID-19Hemato · 2022
  3. Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysisAdvances in Therapy · 2022
  4. Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experienceGynecologic Oncology Reports · 2022
  5. Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM StudyHemato · 2022
  6. Diabetes and COVID-19; A Bidirectional InterplayFrontiers in Endocrinology · 2022
  7. Myocardial work and vascular dysfunction are partially improved at 12 months after COVID ‐19 infectionEuropean Journal of Heart Failure · 2022
  8. Future Developments in the Treatment of AL AmyloidosisHemato · 2022
  9. Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222Biomedicines · 2022
  10. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert ConsensusESMO Open · 2022
  11. Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trialAmerican Journal of Hematology · 2022
  12. Persisting Endothelial Cell Activation and Hypercoagulability after COVID-19 Recovery—The Prospective Observational ROADMAP-Post COVID-19 StudyHemato · 2022
  13. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trialBlood Cancer Journal · 2022
  14. The Mutational Landscape of Early-Onset Breast Cancer: A Next-Generation Sequencing AnalysisFrontiers in Oncology · 2022
  15. The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma CellsBiomedicines · 2022
  16. Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple MyelomaClinical Lymphoma Myeloma & Leukemia · 2022
  17. Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning AnalysisBiomedicines · 2022
  18. Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myelomaTherapeutic Advances in Hematology · 2022
  19. Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell LymphomaIn Vivo · 2022
  20. Chasing Hippos: Implications of YAP1 and TAZ Expression in Pregnancy-associated Breast Cancer TumorigenesisIn Vivo · 2022
  21. An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairmentTherapeutic Advances in Hematology · 2022
  22. A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple MyelomaInternational Journal of Molecular Sciences · 2021
  23. tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular SignatureBiomedicines · 2021
  24. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 InfectionFrontiers in Immunology · 2021
  25. What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of ExperienceCurrent Oncology · 2021
  26. Prothymosin α and its C-Terminal Immunoreactive Decapeptide Show No Evidence of Acute Toxicity: A Preliminary In Silico, In Vitro and In Vivo InvestigationCurrent Medicinal Chemistry · 2021
  27. Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathiesBlood Advances · 2021
  28. Nonselective proteasome inhibitors in multiple myeloma and future perspectivesExpert Opinion on Pharmacotherapy · 2021
  29. Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 PatientsBlood · 2021
  30. Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma NetworkBlood · 2021
  31. ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm: A Cohort Study by the Hellenic GU Cancer GroupCurrent Oncology · 2021
  32. Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapySHILAP Revista de lepidopterología · 2021
  33. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignanciesBlood Advances · 2021
  34. Late‐onset hematological complications post COVID ‐19: An emerging medical problem for the hematologistAmerican Journal of Hematology · 2021
  35. Metabolic Disorders in Multiple MyelomaInternational Journal of Molecular Sciences · 2021
  36. Distinct neutralization profile of spike variants by antibodies induced upon SARS‐CoV ‐2 infection or vaccinationAmerican Journal of Hematology · 2021
  37. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysisHaematologica · 2021
  38. Nocebo-Prone Behavior Associated with SARS-CoV-2 Vaccine Hesitancy in Healthcare WorkersVaccines · 2021
  39. Estimated pulse wave velocity improves risk stratification for all-cause mortality in patients with COVID-19Scientific Reports · 2021
  40. Elucidating Carfilzomib’s Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of MetforminInternational Journal of Molecular Sciences · 2021
  41. Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective StudyCancers · 2021
  42. Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP InhibitorsVaccines · 2021
  43. Pembrolizumab in endometrial cancer: Where we stand now (Review)Oncology Letters · 2021
  44. Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical InfectionFrontiers in Immunology · 2021
  45. Mineralocorticoid receptor signaling is implicated in carfilzomib-induced increase in blood pressureEuropean Heart Journal · 2021
  46. Cardiac amyloidosis presenting with coronary artery embolizationReviews in Cardiovascular Medicine · 2021
  47. Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaquesPLoS Pathogens · 2021
  48. Utilization and tolerance of beta-blockers among patients with AL amyloidosisAmyloid · 2021
  49. Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-AnalysesJournal of Clinical Medicine · 2021
  50. Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective studyBlood Advances · 2021